MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Prevalence and incidence of PSP and CBS: A new prospective study in the UK

J.B. Rowe, I.T. Coyle-Gilchrist (Cambridge, United Kingdom)

Meeting: 2016 International Congress

Abstract Number: 245

Keywords: Cognitive dysfunction, Corticobasal degeneration (CBD), Frontotemporal dementias: Clinical features, Progressive supranuclear palsy(PSP)

Session Information

Date: Monday, June 20, 2016

Session Title: Parkinsonism, MSA, PSP (secondary and parkinsonism-plus)

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To estimate the prevalence and incidence of progressive supranuclear palsy (PSP, ‘Richardson’s syndrome’) and corticobasal syndromes (CBS); in the context of all clinical phenotypes within the spectrum of Frontotemporal Lobar Degeneration (FTLD).

Background: There are limited data on the prevalence and incidence of PSP and CBS, and several factors affect the interpretation of previous data. First, diagnostic criteria for CBS were revised in 2013 to improve sensitivity and specificity for corticobasal degeneration. Second, intermediate phenotypes of uncertain nosological status lie outside former diagnostic categories, e.g. overlap between PSP and CBS. Third, patients may evolve their syndrome, meeting criteria for multiple disorders over time, e.g. PSP may evolve to or from the syndrome of behavioural variant frontotemporal dementia. Finally, previous studies often used widely varying methods, impairing the comparison across reports.

Methods: A prospective study with multiple case referral from specialist and community healthcare services and patient based organisations over 2 years to identify all PSP and CBS, of any age, along with diagnosed or suspected cases of Frontotemporal Dementia, from two UK counties (population 1.7m), adjusting rates to the 2013 European standard population.

Results: We identified 48 people with PSP (29 men, mean age 73, criteria: Litvan et al 1996) and 48 with CBS (17 men, mean age 71, criteria: Armstrong et al 2013). Standardised prevalence was 5.1/100,000 for PSP and CBS combined, with their mortality and incidence matched at 0.8/100,000. Peak prevalence for PSP was 14.5/100,000 at age 70-74, and for CBS 12.5/100,000 at age 75-79 (not including PSP-Parkinsonism or corticobasal degeneration with non-CBS presentations). At assessment, mean 4.6 years from symptom onset, 66% of CBS cases had significant language impairment and 83% of PSP cases had significant behavioural changes.

Conclusions: The prevalences of clinically manifest PSP (Richardson’s syndrome) and CBS are similar, at approximately 2.5 per 100,000 each. Prevalence rises after 65 years. They account for approximately half of the clinical spectrum associated with frontotemporal lobar degeneration. Prevalent cases have frequent language and behavioural change in addition to the core diagnostic features.

To cite this abstract in AMA style:

J.B. Rowe, I.T. Coyle-Gilchrist. Prevalence and incidence of PSP and CBS: A new prospective study in the UK [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/prevalence-and-incidence-of-psp-and-cbs-a-new-prospective-study-in-the-uk/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/prevalence-and-incidence-of-psp-and-cbs-a-new-prospective-study-in-the-uk/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley